35 results about "Valvular heart disease" patented technology

A system is provided for treating valvular disease percutaneously though a ventricular apex of the heart. The system includes a needle for piercing through the ventricular apex of the heart and creating a hole whereby a catheter can be passed through the skin and the wall of the heart to gain access to the interior of the heart. Once percutaneous access to the heart is obtained, any of a variety of techniques can be utilized for annular and / or valvular therapy and / or repair through, the catheter. A closure device is necessary for closing the puncture of the heart. Any of a variety of vascular closure devices can be modified to be utilized with the system to close the puncture of the ventricular apex of the heart.

The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration, thrombosis, and calcification, (2) treating carcinoid heart disease, (3) identifying inhibitors of heart valve degeneration, thrombosis, and calcification, and (4) determining the safety of drugs.

In various embodiments, provided herein are devices, systems and methods using two, three or more pigtails for precisely imaging an aortic valve complex with minimal contrast and / or for advancing an instrument, such as a wire, or device, such as a transcatheter valve, across an aortic valve. In various embodiments, these devices, systems and methods may be used to diagnose and / or treat patients with aortic stenosis, other valvular heart disease or other cardiovascular or non cardiovascular disease, facilitating precise contrast or drug or device delivery, precise pressure measurement and / or precise drainage or sampling. In some embodiments, each of the multiple pigtails of the device may be advanced independently of one another in multiple directions and at multiple lengths of deployment to optimize position.

The invention discloses a valve clamping device for treating valvular heart diseases. The valve clamping device comprises a valve leaflet hook for lifting and fixing a valve leaflet, a clamping part for clamping an object in the clamping part through the interaction force produced by closing up and extrusion, a locking device arranged outside the clamping part and capable of making the clamping part tight in clamping and not displace, and a conveying device for conveying parts to an operation position in a minimally invasive way. The valve clamping device is applied to a lesion valve leaflet,normal chordae tendineae on two sides of the lesion part are close to each other by closing up free edges of the lesion valve leaflet, and accordingly the normal closing-up level of the valve leafletis rehabilitated. The valve clamping device has the advantages of being simple in structure, capable of achieving minimally invasive implantation, easy to operate and good in clamping effect and having clamping parts detachable or adjustable, can be applied to treatment of mitral regurgitation and tricuspid regurgitation and can be also used for other minimally invasive surgeries of several lamellar structures needing clamping.

Stretch-induced increased hemodynamic load adversely affects endothelial cell function and is an important contributor to thromboembolus formation in heart failure, valvular heart disease, atrial fibrillation, venous insufficiency, and pulmonary hypertension, and in thrombus occluded vein grafts. Local thrombus formation and thromboenbolic events can be reduced by inhibiting the TGF-beta signaling pathway or TGF-beta per se. Inhibitors can be administered to patients or veins (prior to interposition) at risk for thromboembolic events or local thrombus formation. Inhibitors can be applied to harvested veins to be used as arterial grafts.

The present invention provides methods for preventing or treating a valvular stenosis or a valvular calcification in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a peptide / phospholipid complex, wherein the peptide of the complex is an Apolipoprotein A-1 mimetic peptide. In one embodiment the Apolipoprotein A-1 mimetic peptide has the sequence set forth in SEQ ID NO: 1. In another embodiment the phospholipid of the complex is egg sphingomyelin and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine.

A method for treating valvular stenosis. The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal. Most preferred is an Apolipoprotein A-1 mimetic peptide / phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.

The invention provides an universal intervention instrument stabilizer for valvular heart disease, which comprises a base, a plane rotating device, a mechanical arm, a sliding rail, a supporting platform, a clamping jaw and a joint capable of rotating universally, the base is connected with the plane rotating device, the plane rotating device is connected with the mechanical arm, the mechanical arm extends away from the plane rotating device and capable of keeping a bending shape, the top end of the mechanical arm is connected with a sliding rail through one joint, the supporting platform is slidably arranged in the sliding rail, and the supporting platform is connected with the clamping jaw through the other joint. According to the universal intervention instrument stabilizer for valvular heart disease, an intervention instrument can be assisted to keep in stable during an interventional operation, and particularly can ensure that the movement direction of an instrument is consistent with the bending direction of the front end of a catheter when Lux-Valve is applied to transcatheter tricuspid valve replacement, so that the surgeon is helped to control the intervention instrument, conveying and releasing of the artificial valve are completed, and the operation efficiency is improved.

The present invention provides modular transcatheter valve replacement devices and methods of using the same to treat valvular heart diseases. Disclosed is a bottom module that contains a heart valve replacement, and a top module connected to the bottom module. The top module may be bio-absorbable, or may contain one or more severable joints that allow the top module to be removed after implantation. The removable or absorbable top portion serves to add additional length the structure to add in orientation during implantation, but is removed or absorbed to minimize the metal and other foreign material in a patient's body that could cause thrombosis or other reactions.

The invention provides a multi-protein combined biomarker, application and a heart valvular disease complicated with atrial fibrillation diagnostic kit. The multi-protein combined biomarker is composed of an apolipoprotein A1 protein antibody, an angiotensin antigen antibody, an LIM structural domain protein 7, a macrophage colony stimulating factor receptor 1, a vitronectin antibody and a prothrombin fragment F1 + 2 antibody. Modern biological technology and bioinformatics analysis find that combined application of the six proteins has the application of predicting valvular heart disease complicated with atrial fibrillation, can be applied to preparation of targeted drugs for early intervention of related diseases, and can also be applied to preparation of a heart valvular disease complicated with atrial fibrillation screening kit. According to the kit, modeling is carried out after the concentrations of the six proteins are measured, and good evaluation efficiency and potential hugeapplication value are achieved on whether atrial fibrillation happens to a patient suffering from the heart valvular disease or not.

The invention relates to a valve clip. The valve clip includes a first valve clip and a second valve clip; the first valve clip is woven by titanium nickel alloy wires and includes a first clip body in an annular opening structure; the bottom inside the first clip body is connected to a steel cable structure; the second valve clip is made of stainless steel and includes a second clip body, two fixing supports, a fixing ring and a hardening pipe; the fixing ring is in a circular structure and fixedly connected to the bottom of the second clip body; the front ends of the fixing supports are respectively and fixedly connected to the end section of the second clip body, and the tail ends of the fixing supports are fixedly connected to the central position at the bottom of the fixing ring; andthe hardening pipe is arranged in the bottom of the second clip body and between the two fixing supports. The advantages of the valve clip are as follows: interventional therapy can be performed on the patients with mitral, tricuspid and aortic insufficiency in valvular heart diseases; the valve clip is simple in operation, small in trauma, fast in recovery and wide in indication.

The invention discloses a bionic modified valve material as well as a preparation method and application thereof. The preparation method comprises the following steps: A, synthesizing drug-loaded nanoparticles for loading drugs; B, preparing cell membrane vesicles; C, mixing the drug-loaded nanoparticles with cell membrane vesicles, and performing extruding for multiple times to prepare drug-loaded nanoparticles wrapped with cell membranes; and D, crosslinking the drug-loaded nanoparticles wrapped with cell membranes to the surface of a bioprosthetic valve to obtain the bionic modified valve material. The method disclosed by the invention has the advantages of simplicity in operation, mild reaction conditions and the like, and the bionic modified valve material prepared of the drug-loadednanoparticles wrapped with cell membranes, prepared by the method disclosed by the invention can be used for well solving the problems of easiness in thrombus and calcification, endothelialization difficulty and the like of an existing glutaraldehyde cross-linked valve. Besides, a strategy of combining a cell membrane bionic drug delivery system with the valve provides a new generation of treatment mode for safe and efficient treatment of valvular heart diseases.

Devices, systems and methods using two, three or more pigtails for precisely imaging an aortic valve complex with minimal contrast and / or for advancing an instrument, such as a wire, or device, such as a transcatheter valve, across an aortic valve. These devices, systems and methods may be used to diagnose and / or treat patients with aortic stenosis, other valvular heart disease or other cardiovascular or non cardiovascular disease, facilitating precise contrast or drug or device delivery, precise pressure measurement and / or precise drainage or sampling.

The invention discloses ganoderma lucidum spore oil and a novel application of a pharmaceutical composition comprising the ganoderma lucidum spore oil to preparing functional foods and drugs having effects of preventing myocardial fibrosis caused by aorta valvular heart diseases. The invention discloses the ganoderma lucidum spore oil and the novel application of the pharmaceutical composition comprising the ganoderma lucidum spore oil to preventing the myocardial fibrosis caused by the aorta valvular heart diseases for the first time, a novel method is provided for preventing the myocardial fibrosis caused by the aorta valvular heart diseases, the ganoderma lucidum spore oil prepared by using the preferential method in the invention and a drug prepared from the ganoderma lucidum spore oileffectively prevent fibrosis and have the effects of preventing ventricular remodeling and heart failure.

The invention provides a novel marker for auxiliary diagnosis of a valvular heart disease and an auxiliary diagnosis product. According to the present invention, a novel biomarker PLAUR capable of being adopted as the auxiliary diagnosis of the valvular heart disease is found for the first time, the detection speed is rapid, the result can be obtained only in one workday, at the same time, the detection sensitivity / accuracy is far higher than the NT-ProBNP and the hsCRP, and the high-throughput operation can be achieved.

There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of cardiovascular diseases, and method for the treatment thereof. The cardiovascular diseases (CVD) may comprise several diseases associated with inflammation of the heart or arteries and include coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack), atherosclerosis, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

The invention discloses a bionic modified valve material and its preparation method and application, comprising the following steps: A. synthesizing drug-loaded nanoparticles loaded with drugs; B. preparing cell membrane vesicles; C. combining drug-loaded nanoparticles with cell membrane vesicles Bubble mixing and extruding for multiple times to prepare cell membrane-wrapped drug-loaded nanoparticles; D. cross-linking cell membrane-wrapped drug-loaded nanoparticles to the surface of the biovalve to obtain the final product. The method of the present invention has the advantages of simple operation, mild reaction conditions, etc., and the bionic modified valve material prepared by the method of the present invention wraps nanometer drug-loaded particles, which can well solve the problems of easy thrombosis, calcification and Endothelialization difficulties and other problems. At the same time, the strategy of combining the cell membrane bionic drug delivery system with the valve provides a new generation of treatment mode for the safe and efficient treatment of valvular heart disease.

The invention discloses a construction method of a drug screening system for treating senile valvular heart disease by using a single traditional Chinese medicine. The construction method specifically comprises the following steps of constructing pmirGLO-RAGE5'-UTR and pmirGLO-mut-RAGE vectors; annealing the target fragment of the gene to synthesize double-stranded DNA, performing thermal denaturation at 95 DEG C for 2 minutes, lowering the temperature by 1 DEG C every 90 seconds to 25 DEG C, standing for 30 minutes, storing at 4 DEG C, and performing cryopreservation at -20 DEG C for later use; carrying out double enzyme digestion on the pmir GLO vector by using Sac I and Xho I enzymes so as to unlink the pmir GLO vector to be linearized; carrying out DNA recovery on a double-enzyme digestion product through agarose gel electrophoresis, and connecting the linear vector with the RAGE5 '-UTR vector; connecting the mutant target fragments by the same method to construct mutant recombinant vector plasmids; transforming the two recombinant vector plasmids and the no-load plasmid into escherichia coli DH5 alpha, picking bacterial colonies, and extracting and identifying the plasmids; and culturing 293T cells, transferring the 293T cells into plasmids containing recombinant pmirGLO-RAGE5'-UTR or pmirGLO-mut-RAGE through LipofectamineTM2000, transfecting for 24 hours, detecting the transfection efficiency, and selecting stably transfected cells, thereby successfully constructing the screening system. The screening system is simple and effective, and target sites can be replaced for popularization and application.

Medium chain fatty acids or a composition comprising medium chain fatty acids for use in the prevention or treatment of cardiac enlargement, valvular heart disease and / or a condition associated with either of the foregoing in a human.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure.

The present invention relates to a novel use of drugs and particularly discloses an application of finerenone in preparation of drugs for treatment of senile calcific valvular heart diseases. Studiesshow that finerenone is a third-generation aldosterone receptor antagonist with strong affinity for mineralocorticoids, antagonizes a series of pathological processes caused by excessive activation ofthe mineralocorticoids by aldosterone by competitively binding mineralocorticoid receptor (MR), thus regulates cell proliferation, differentiation and apoptosis, significantly improves degenerative changes of heart valve connective tissues, fibrosis, thickening and calcification, and protects cardiomyocytes. Compared with the prior art, the finerenone can reduce various indexes of senile patientswith the calcific valvular heart diseases, improves disease conditions, and improves life quality of the senile patients with the calcific valvular heart diseases.

Medium chain fatty acids or a composition comprising medium chain fatty acids for use in the prevention or treatment of cardiac enlargement, valvular heart disease and / or a condition associated with either of the foregoing in a human.

The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration, thrombosis, and calcification, (2) treating carcinoid heart disease, (3) identifying inhibitors of heart valve degeneration, thrombosis, and calcification, and (4) determining the safety of drugs.

The present invention relates to the use of a serotoninergic receptor antagonist, such as sarpogrelate or compositions thereof, for the treatment and / or prevention of heart damages in mammals.

Stretch-induced increased hemodynamic load adversely affects endothelial cell function and is an important contributor to thromboembolus formation in heart failure, valvular heart disease, atrial fibrillation, venous insufficiency, and pulmonary hypertension, and in thrombus occluded vein grafts. Local thrombus formation and thromboenbolic events can be reduced by inhibiting the TGF-beta signaling pathway or TGF-beta per se. Inhibitors can be administered to patients or veins (prior to interposition) at risk for thromboembolic events or local thrombus formation. Inhibitors can be applied to harvested veins to be used as arterial grafts.

The present invention provides modular transcatheter valve replacement devices and methods of using the same to treat valvular heart diseases. Disclosed is a bottom module that contains a heart valve replacement, and a top module connected to the bottom module. The top module may be bio-absorbable, or may contain one or more severable joints that allow the top module to be removed after implantation. The removable or absorbable top portion serves to add additional length the structure to add in orientation during implantation, but is removed or absorbed to minimize the metal and other foreign material in a patient's body that could cause thrombosis or other reactions.

There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of cardiovascular diseases, and method for the treatment thereof. The cardiovascular diseases (CVD) may comprise several diseases associated with inflammation of the heart or arteries and include coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack), atherosclerosis, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

The invention relates to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine for treating a rheumatic valvular heart disease. The traditional Chinese medicine for treating the rheumatic valvular heart disease is prepared from the following raw materials according to a weight proportion: traditional Chinese medicines such as dangshen, mangnolia officinalis, caulis spatholobi, angelica sinensis, ephedra, radix dipsaci, cloves, tuckahoe, fructus amomi, longan aril, semen cassiae, fructus piperis longi, radix ophiopogonis, polygala tenuifolia, lithargite, fruits of Chinese wolfberry, blumea balsamifera, elecampane, smoked plum, humulus scandens, cowherb seed, honey and liquorice. The medicines adopted by the traditional Chinese medicine supplement each other, and the traditional Chinese medicine is prepared according to a formula of a traditional Chinese medicine theory and a certain weight proportion, has an obvious curative effect on treating the rheumatic valvular heart disease, has the characteristics of safety, reliability, low cost, simplicity in preparation, obvious curative effect and the like, has the effects of dispelling wind, eliminating dampness, regulating qi to alleviate pain, replenishing and activating blood, tonifying spleen and stomach, nourishing heart and calming nerves and has an excellent effect on restoring valves.

The invention discloses a capsule for treating senile calcific valvular heart disease and a preparation method thereof, so as to solve the problem of cardiac valve calcification is difficult to treat. The preparation method is characterized by comprising the following steps: (1) distilling tetrapanax papyriferum, fruit of rosa davurica pall and littleflower stringbush bark and root through water vapor to extract volatile oil for standby, and storing the decoction dregs for standby; (2) crushing gecko and coked rice sprout into fine powder for standby; (3) uniformly mixing persimmon bark, sunglow, poncirus bark, horsetail, filipendula palmata (pall) maxim, fiveleaf akebia fruit and nakedflower beautyberry branchlet and leaf with the decoction dregs obtained in the step 1, extracting the mixture with alcohol for twice, mixing the two alcohol extracting solutions, filtering, recycling ethanol, and concentrating the filtrate to extract at reduced pressure; (4) adding the fine powder obtained in the step 2 in the extract obtained in the step 3, mixing evenly, drying the mixture at 60 DEG C, crushing the mixture into fine powder, adding polysorbate-80 in the mixture to prepare granules, drying, trimming the granules, spraying the volatile oil obtained in the step 1, mixing evenly, and filling a capsule with the mixture to obtain the capsule. Clinical experiments prove that the capsule for treating senile calcific valvular heart disease disclosed by the invention has the advantages of good curative effect and high safety, so that the capsule is worthy of clinical application and popularization.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure.